Beta Bionics

Pharmacy Channel Adoption And Bihormonal Pipeline Will Drive Long Term Diabetes Care Impact

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

14 Dec 25

Views

n/a

AnalystConsensusTarget's Fair Value

n/a

2.1%

n/a

2.1%

You can edit this narrative until Dec 15 10:05 PM. Then, changes will post as Updates.

Author's Valuation

US$31.35.3% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

US$31.3

5.3% undervalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

28.44%

Medical Equipment revenue growth rate

7.79%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.68%

Calculation

US$30.32m

Earnings '28

59.43x

PE Ratio '28

US$1.80b

Market Cap '28

US$1.80b

Market Cap '28

46.12m

No. shares '28

US$39.07

Share Price '28

US$39.07 Share Price '28

Discounted to 2025 @ 7.67% p.a.

US$31.30

Fair Value '25